An investigation for investors in NYSEMKT:TRXC shares was announced over possible securities laws violations by Transenterix in connection certain financial statements.
Investors who purchased shares of Transenterix Inc (NYSEMKT:TRXC), have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 – 1554.
The investigation by a law firm focuses on whether a series of statements by Transenterix regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Morrisville, NC based TransEnterix, Inc. is a medical device company that is focused on the development and commercialization of ALF-X Surgical Robotic System and SurgiBot System. On April 20, 2016, Transenterix Inc announced that the Food and Drug Administration (“FDA”) notified Transenterix Inc on April 19, 2016 of its determination that the “SurgiBot™ System does not meet the criteria for substantial equivalence based upon the data and information submitted by TransEnterix in its 510(k) submission.” Shares of Transenterix Inc (NYSEMKT:TRXC) declined to a slow as $1.28 per share on April 21, 2016.
Those who purchased NYSEMKT:TRXC shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego